AGO2 and breast cancer: The 31-nt tRFMet generated by the argonaute 2 (Ago2)-induced cleavage of translation initiator aminoacyl-tRNA (tRNAiMet) blocks angiogenesis in breast cancer by targeting the glycolytic enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 (PFKFB3) [55], while tRFGln reduces angiogenesis by inhibiting Antxr1 [56], a tumor angiogenesis marker.